Most Searched
Originally published November 17, 2026
Last updated November 17, 2026
Reading Time: 3 minutes
Search more articles
News & Magazine
Topics
For primary care physicians managing patients with renal masses or suspected kidney cancer, timely referral to a specialized urologic oncologist is essential. When and how to refer a patient to a specialist is not always straightforward, however.
Hooman Djaladat, MD, is a urologist with the USC Urologic Oncology Program, part of USC Urology and the USC Norris Comprehensive Cancer Center of Keck Medicine of USC.
He offers five key considerations for primary care and community providers.
“Any mass or complex cyst of kidney seen on imaging study, except for a simple cyst, warrants urologic evaluation,” Djaladat says. Simple cysts are common and do not require referral. However, complex cystic lesions and solid masses demand further characterization as there is high chance of malignancy.
Triple-phase contrast-enhanced CT or MRI with contrast are the preferred imaging modalities for evaluating suspected renal cell carcinoma (RCC).
Microscopic or gross hematuria — blood in urine — can signal kidney cancer invading the collecting system.
“Any hematuria requires further workup,” Djaladat says. Such additional testing may include cystoscopy and upper tract imaging.
The American Urological Association guidelines recommend risk-stratified evaluation, with urology referral for patients at intermediate or high risk of urothelial or renal malignancy. Risk factors include a history of smoking, occupational exposures and hereditary syndromes.
While renal tumors are typically asymptomatic and discovered incidentally, unexplained flank pain or a palpable flank mass should trigger referral.
“Kidney tumors generally don’t cause pain,” Djaladat says. “But occasionally they can, so unexplained flank pain needs evaluation.”
Palpable masses, whether renal or retroperitoneal, require urologic or surgical oncology consultation.
Patients with hereditary syndromes such as Von Hippel-Lindau disease, Birt-Hogg-Dubé syndrome or hereditary papillary RCC require genetic testing and specialized surveillance.
“Additionally, any patient with a history of kidney cancer on one side is at risk of developing it on the other side,” Djaladat says. These patients benefit from referral for annual imaging and surveillance planning.
Patients who have undergone partial or radical nephrectomy for RCC require ongoing follow-up to monitor for recurrence or new primary tumors.
“I believe sometimes patients and practitioners are under the wrong impression that once the tumor is cut out and treated, you’re fine,” Djaladat says. These patients should be followed by a urologic oncologist to determine appropriate imaging intervals and modality.
Early referral is particularly critical for patients with:
Although there has been an increase in diagnosis of kidney cancers due to more common use of cross-sectional imaging, Djaladat notes that patients still could be diagnosed in late stages, as they are asymptomatic most of the time. It is noteworthy to highlight that patients with hereditary syndromes or prior kidney cancer should be referred and closely followed up by specialist.
Refer patients to urologic oncology for comprehensive evaluation and management planning. Academic health systems like Keck Medicine offer multidisciplinary teams with expertise in complex kidney cancer management and access to clinical trials on novel therapies.
Share